Loma Linda University

Enrollment Information
Call us at: 909-558-1000

Faculty Directory
  
James Slater, MD
Vice Chair, Basic Sciences, Radiation Research Division
School of Medicine
Professor, Radiation Medicine
School of Medicine
Professor, Basic Sciences
School of Medicine
Publications    Book Review - Scholarly Journals--Published   Scholarly Journals--Published
  • Tian J, Pecaut MJ, Coutrakon GB, Slater JM, Gridley DS.  Response of extracellular matrix regulators in mouse lung after exposure to photons, protons and simulated solar particle event protons. Radiat Res. 2009 Jul;172(1):30-41. ( 7/2009 - 8/2009 )
  • Makinde AY, Luo-Owen X, Rizvi A, Crapo JD, Pearlstein RD, Slater JM, Gridley DS.  Effect of a metalloporphyrin antioxidant (MnTE-2-PyP) on the response of a mouse prostate cancer model to radiation. Anticancer Res. 2009 Jan;29(1):107-18. ( 1/2009 )
  • Gridley DS, Slater JM, Luo-Owen X, Rizvi A, Chapes SK, Stodieck LS, Ferguson VL, Pecaut MJ. Spaceflight effects on T lymphocyte distribution, function and gene expression. J Appl Physiol. 2009 Jan;106(1):194-202. Epub 2008 Nov 6.   ( 1/2009 )
  • Gridley DS, Makinde AY, Luo X, Rizvi A, Crapo JD, Dewhirst MW, Moeller BJ, Pearlstein RD, Slater JM:  Radiation and a metalloporphyrin radioprotectant in a mouse prostate tumor model.  Anticancer Res 2007 Sep-Oct;27(5A):3101-9 ( 9/2008 )
    BACKGROUND: Antioxidants have the potential to protect normal tissues against radiation-induced damage, but must not protect tumor cells during radiotherapy. The major objectives were to determine whether a metalloporphyrin antioxidant affects prostate tumor response to radiation and identify possible mechanisms of interaction. MATERIALS AND METHODS: C57BL/6 mice with RM-9 tumor were treated with manganese (III) meso-tetrakis (1,3-diethylimidazolium-2-yl) porphyrin (MnTDE-2-ImP) and 10 gray (Gy) radiation. Tumor volume was quantified and a subset/group was evaluated for hypoxia-inducible factor-1alpha (HIF-1alpha), bone marrow-derived cell populations and cytokines. RESULTS: The addition of MnTDE-2-ImP transiently increased tumor response compared to radiation alone. The group receiving drug plus radiation had reduced intratumoral HIF-1alpha and decreased capacity to secrete TNF-alpha, whereas production of IL-4 was increased. There were no toxicities associated with combination treatment. CONCLUSION: The results demonstrate that MnTDE-2-ImP did not protect the RM-9 prostate tumor against radiation; instead, radiation effectiveness was modestly increased. Possible mechanisms include reduction of radiation-induced HIF-1alpha and an altered cytokine profile.
  • Gridley DS, Coutrakon GB, Rizvi A, Bayeta EJ, Luo-Owen X, Makinde AY, Baqai F, Koss P, Slater JM, Pecaut MJ:  Low-dose photons modify liver response to simulated solar particle event protons.  Radiation Research, 2008 Mar;169(3):280-7. ( 9/2008 )
    The health consequences of exposure to low-dose radiation combined with a solar particle event during space travel remain unresolved. The goal of this study was to determine whether protracted radiation exposure alters gene expression and oxidative burst capacity in the liver, an organ vital in many biological processes. C57BL/6 mice were whole-body irradiated with 2 Gy simulated solar particle event (SPE) protons over 36 h, both with and without pre-exposure to low-dose/low-dose-rate photons ((57)Co, 0.049 Gy total at 0.024 cGy/h). Livers were excised immediately after irradiation (day 0) or on day 21 thereafter for analysis of 84 oxidative stress-related genes using RT-PCR; genes up or down-regulated by more than twofold were noted. On day 0, genes with increased expression were: photons, none; simulated SPE, Id1; photons + simulated SPE, Bax, Id1, Snrp70. Down-regulated genes at this same time were: photons, Igfbp1; simulated SPE, Arnt2, Igfbp1, Il6, Lct, Mybl2, Ptx3. By day 21, a much greater effect was noted than on day 0. Exposure to photons + simulated SPE up-regulated completely different genes than those up-regulated after either photons or the simulated SPE alone (photons, Cstb; simulated SPE, Dctn2, Khsrp, Man2b1, Snrp70; photons + simulated SPE, Casp1, Col1a1, Hspcb, Il6st, Rpl28, Spnb2). There were many down-regulated genes in all irradiated groups on day 21 (photons, 13; simulated SPE, 16; photons + simulated SPE, 16), with very little overlap among groups. Oxygen radical production by liver phagocytes was significantly enhanced by photons on day 21. The results demonstrate that whole-body irradiation with low-dose-rate photons, as well as time after exposure, had a great impact on liver response to a simulated solar particle event.
  • Gridley DS, Rizvi A, Luo-Owen X, Makinde AY, Coutrakon GB, Koss P, Slater JM, Pecaut MJ. Variable hematopoietic responses to acute photons, protons and simulated solar particle event protons.  In Vivo. 2008 Mar-Apr;22(2):159-69. ( 3/2008 - 4/2008 )
  • James M. Slater, MD, FACR. "Selecting the optimum particle for radiation therapy." Technology in Cancer Research & Treatment 6.4 (2007): 35-39. ( 8/2007 ) Link...
  • David A. Bush, MD, Jerry D. Slater, MD, Carlos Garberoglio, MD, Grace Yuh, MD, Janet M. Hocko, MD, and James M. Slater, MD. "A Technique of Partial Breast Irradiation Utilizing Proton Beam Radiotherapy: Comparison with Conformal X-ray Therapy." The Cancer Journal 13.2 (2007): 114-118. ( 4/2007 )
  • Luu QT, Levy RP, Miller DW, Shahnazi K, Yonemonto LT, Slater JM, Slater JD. "Technol. Cancer Res. Treat. ." 275.82 (2005): -. ( 6/2005 )
    Location- Radiation Medicine PMID 15896083 Code-2
  • Luo X, Andres M, Slater JM, Gridley DS. "Proc. of the AARC." 46.790 (2005): -. ( 4/2005 )
    Presented at the 96th annual meeting of the American for Cancer Reserach (AARC) Anaheim, CA
  • Makinde AY, Rizvi A, Luo X, Andres M, Archambeau JO, Pearlstein RD, Slater JM, Gridley DS. "Proc. of the AARC." 46.466 (2005): -. ( 4/2005 )
    Presented at the 96th Annual Meeting of the American Assocition for the Cancer Reserach (AARC)
  • Gridley DS, Slater JM. "Gene Therapy: A possible Aid to Cancer Radiotherapy." Discovery Medicine 4.24 (2004): 408-414. ( 12/2004 )
    Location- CSP A-1010 Code- 1
  • James M. Slater, MD, FACR. "Selecting the optimum particle for radiation therapy." Technology in Cancer Research and Treatment . (): -. (*)
  • James M. Slater, MD, FACR. "Developing and Understanding a Hospital-based Proton Facility: Bringing Physics into Medicine." Technology in Cancer Research and Treatment . (): -. (*)
  Non-Scholarly Journals
  • Editorial Board of the James M. Slater, MD Proton Treatment and Research Center Newsletter ( 9/2009 )